ALLMedicine™ Acid Phosphatase Center

Jan 12th, 2022 - Idiopathic pulmonary fibrosis (IPF) is a fatal interstitial lung disease with limited therapeutic options. Tartrate-resistant acid phosphatase 5 (ACP5) performs a variety of functions. However, its role in IPF remains unclear. Here, we demonstrate...

Jan 10th, 2022 - Matrix protein is secreted by the membrane of bivalve shellfish to and used to regulate shell biomineralization. In this study, we extracted water-soluble matrix protein (WSMP) from oyster shells to investigate its effects on osteogenic differenti...

Jan 7th, 2022 - To evaluate and compare the effects of the combined intervention of metformin and exercise on the degeneration of cartilage and subchondral bone in a mouse model of osteoarthritis (OA) induced by estrogen deficiency and obesity. 56 female 3-month-...

Jan 6th, 2022 - In the present study, the purpose is to compare the effect of water extraction and alkali-assisted extraction on the structural characteristics and immunomodulatory activity of polysaccharides from Fuzhuan brick tea (FBTPs). The results indicated ...

Jan 6th, 2022 - Type 2 diabetes (T2D)-associated periodontitis is severe and refractory in many cases. Considered an inflammatory disease, T2D predisposes to periodontitis by increasing whole-body inflammation. One mechanism of increased inflammation is thatT2D i...

Oct 30th, 2017 - Castration-resistant prostate cancer (CRPC) develops serial treatment resistance and is considered incurable. It is a largely indolent disease, which would give the body time to mount an effective immune response. CRPC is therefore potentially wel...

Feb 11th, 2013 - OBJECTIVES: I. Determine the efficacy of APC8015 (Provenge) and bevacizumab, in terms of decline in prostate-specific antigen (PSA) value and effect on PSA doubling time, in patients with progressive prostate cancer. II. Determine any immune respo...

Nov 1st, 2010 - Objectives: I. Compare the time to progression, time to development of disease-related pain, and incidence of grade 3 or worse treatment-related adverse events in patients with asymptomatic metastatic hormone refractory adenocarcinoma of the prost...

Oct 6th, 2021 - Sumit Subudhi, MD, PhD A subset of patients with metastatic castration-resistant prostate cancer (mCRPC) who have low tumor mutational burden (TMB) may benefit from checkpoint inhibition with ipilimumab (Yervoy) if the tumor has a high density of...

Oct 6th, 2021 - Nicholas J. Vogelzang, MD In a recent guideline for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC), the American Society of Clinical Oncology (ASCO) and Cancer Care Ontario (CCO) shared their thoughts on the imp...

Oct 6th, 2021 - Emmanuel S. Antonarakis, MBBCh Sipuleucel-T (Provenge) is effective when given either before or after androgen deprivation therapy (ADT) in men with biochemically recurrent prostate cancer (BRPC) who face a high risk of developing metastases, a s...

Oct 6th, 2021 - An immunotherapy drug for the treatment of prostate cancer, approved in the US in 2010, will soon be available in Europe, the maker of the medicine, Dendreon Corporation, announced today. Sipuleucel-T (Provenge) initially will be available in Ger...

Oct 6th, 2021 - Joshua M. Lang, MD Assistant Professor of Medicine University of Wisconsin Carbone Cancer Center The last 10 years have shown tremendous advances in the development of targeted therapeutics for patients with advanced cancer. Ranging from a...